Pharsight Invited to Present on Oncology Modeling and Simulation at AAPS National Biotechnology Conference on June 28, 2007Dr. Rene Bruno Will Present on the Value of Model-Based Predictions of Tumor Growth Dynamics in Clinical Oncology Studies as Part of AAPS Short Course
MOUNTAIN VIEW, Calif., June 26, 2007 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that Rene Bruno, Ph.D., managing director, Strategic Consulting Services, Europe has been invited to speak to members of the biotechnology and pharmaceutical industries attending the 2007 AAPS National Biotechnology Conference, to be held in San Diego, California at the San Diego Convention Center on June 24-27, 2007.
Dr. Bruno will present two case studies on novel approaches to integrate modeling and simulation into the development cycle of oncology targeted biotech products. The title of Dr. Bruno's presentation is "Model-based Predictions of Tumor Growth Dynamics in Clinical Oncology Studies." Dr. Bruno's talk is part of a post-conference short course, organized and delivered by experts from industry and academia, on the role of pharmacokinetic/pharmacodynamic (PK/PD) modeling for biotechnology products to support FDA's Critical Path Initiative. The course will include a regulatory perspective from FDA and applied examples of model-based drug development in oncology that describe research on how modeling and simulation has been used to predict expected clinical outcomes and support decision-making. A panel discussion will also provide a forum for scientific discussion and collaborative exchange on implementing novel approaches in oncology drug development. Additional information can be found at http://www.aapspharmaceutica.com/meetings/biotec/bt07/index.asp.
"Model-based drug development continues to show value for improving the quality of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development in oncology can benefit from the quantitative application of drug-disease models using longitudinal data to simulate expected clinical response of new compounds, and to support critical program strategy and study design decisions. Pharsight is pleased to be invited to share its expertise in oncology modeling and simulation with industry colleagues, and to exchange information on challenges and opportunities for the strategic use of quantitative modeling in anticancer drug development."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders
CONTACT: investors, Jennifer Beugelmans, +1-646-201-5447, or DouglasSherk, +1-415-896-6820, or media, Jennifer Saunders, +1-646-201-5431, allof EVC Group for Pharsight Corporation
Web site: http://www.pharsight.com/
Ticker Symbol: (NASDAQ-OTCBB:PHST)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: June 2007
Recommended for you